Obesity Pathway Innovation Programme
Supports health systems in the United Kingdom to pilot coordinated obesity care pathways through integrated prevention and treatment services.
OPIP Strand 3 is a £85M co-funded programme (DSIT £50M, Eli Lilly £35M) for NHS bodies to pilot integrated obesity care pathways combining an access/management service with a care pathway service. Eligible lead applicants are NHS Integrated Care Boards (England), Health Boards (Scotland), local health boards (Wales), and HSC trusts (Northern Ireland). Total eligible costs per project: £2–8M; 100% grant funded. Minimum £10M ring-fenced for devolved administration health services. The Strand 3 competition closed 19 November 2025; interviews ran 19–27 January 2026; projects started by 1 May 2026 and run to 31 March 2029. This programme is effectively closed and in delivery phase. A successor round has not been announced. The programme is unusual for DSIT: it is NHS-public-sector-only in eligibility and carries an industry co-funder (Eli Lilly).
No upcoming rounds verified. Cadence: One-off.